The aim of this study was to investigate the clinical and oxidative profile, including the activity of the
enzyme delta-aminolevulinate dehydratase (δ-ALA-D), in women who acquired
toxoplasmosis during pregnancy and used the triple regimen (sulfadiazine + pyrimethamine + folinic
acid [SPFA]) as treatment. These parameters have not been evaluated in pregnant women with
toxoplasmosis who used the triple regimen. A total of 53 pregnant women were recruited and divided into two groups: control (C; n = 27) and acute
toxoplasmosis (AT; n = 26). Clinical data and blood samples were obtained from all patients. The clinical profile was analyzed by checking parameters such as body mass index, blood pressure, and complete blood count. Oxidative stress was evaluated by quantifying
protein (P-SH) and non-
protein (NP-SH)
thiol groups,
vitamin C, plasma
iron reduction capacity (FRAP), δ-ALA-
D enzyme activity, reactive substances to
thiobarbituric acid (
TBARS), and
nitric oxide (NO). Changes in hematological parameters (increased red cell distribution width and decreased
hemoglobin and mean corpuscular hemoglobin concentration), increased
antioxidant system (P-SH, NP-SH, FRAP, δ-ALA-
D enzyme activity), as well as damage markers (
TBARS and NO), were significantly elevated in pregnant women with
toxoplasmosis, compared to those in the control group. Pregnant women treated for this acute
infection showed increased damage markers, as well as a significant increase in the
antioxidant system, including the activity of the δ-ALA-
D enzyme. Given this evidence, it is suggested that these changes occur as a form of compensation, with a possible contribution from
drug therapy.